IL10 and neoplasm: In the former case, i.e., non-inflammatory cancers in which protective type-1 responses are suppressed by high Treg infiltration, Treg may mainly recognize tumor-associated self-antigens, and mostly include tTreg; conversely, in the case of inflammatory cancers, related to chronic low-dose type-17 cytokines, which are typical of mucosal tissues, high numbers of pTreg may suppress pro-tumoral inflammation through IL-10, relevantly produced by pTreg at those sites.